Company news

Aldeyra Therapeutics, Inc. news in 2024

Aldeyra Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

December 1, 2024

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

November 17, 2024

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

November 13, 2024

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

October 30, 2024

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

September 4, 2024

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

August 7, 2024

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

August 6, 2024

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

June 19, 2024

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

June 12, 2024

Aldeyra Therapeutics to Host Investor Roundtable Q&A

June 11, 2024

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2024

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

May 7, 2024

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

April 24, 2024

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

April 17, 2024

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

March 27, 2024

Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

January 3, 2024

Decks in 2024